

### - 1 CELLS INTERNATION OF CELLS ALLE CHIEF CHI

(43) International Publication Date 11 November 2004 (11.11.2004)

**PCT** 

# (10) International Publication Number WO 2004/096131 A3

(51) International Patent Classification<sup>7</sup>: A61K 31/445, C07D 401/14

(21) International Application Number:

PCT/US2004/012188

(22) International Filing Date: 20 April 2004 (20.04.2004)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data: 60/465,260

24 April 2003 (24.04.2003) US

- (71) Applicant (for all designated States except US): MERCK & CO., INC. [US/US]; 126 East Lincoln Avenue, Rahway, NJ 07065-0907 (US).
- (72) Inventors; and
- (75) Inventors/Applicants (for US only): BILODEAU, Mark, T. [US/US]; 126 East Lincoln Avenue, Rahway, NJ 07065-0907 (US). DUGGAN, Mark, E. [US/US]; 126 East Lincoln Avenue, Rahway, NJ 07065-0907 (US). HARTNETT, John, C. [US/US]; 126 East Lincoln Avenue, Rahway, NJ 07065-0907 (US). LINDSLEY, Craig, W. [US/US]; 126 East Lincoln Avenue, Rahway, NJ 0706-0907 (US). WU, Zhicai [CN/US]; 126 East Lincoln Avenue, Rahway, NJ 07065-0907 (US). ZHAO, Zhijian [CN/US]; 126 East Lincoln Avenue, Rahway, NJ 07065-0907 (US).
- (74) Common Representative: MERCK & CO., INC.; 126 East Lincoln Avenue, Rahway, NJ 07065-0907 (US).

- (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
- (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

#### Published:

- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments
- (88) Date of publication of the international search report: 3 November 2005

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: INHIBITORS OF AKT ACTIVITY

(57) Abstract: The present invention is directed to compounds which contain a substituted pyridine moiety which inhibit the activity of Akt, a serine/threonine protein kinase. The invention is further directed to chemotherapeutic compositions containing the compounds of this invention and methods for treating cancer comprising administration of the compounds of the invention.

### INTERNATIONAL SEARCH REPORT

International application No.

PCT/US04/12188

A. CLASSIFICATION OF SUBJECT MATTER						
IPC(7) : A61K 31/445, C07D 401/14 US CL : 514/322; 546/199						
US CL: 514/322; 546/199 According to International Patent Classification (IPC) or to both national classification and IPC						
B. FIELD	OS SEARCHED					
Minimum documentation searched (classification system followed by classification symbols) U.S.: 514/322; 546/199						
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched						
Electronic data base consulted during the international search (name of data base and, where practicable, search terms used) Please See Continuation Sheet						
C. DOCL	JMENTS CONSIDERED TO BE RELEVANT	Relevant to claim No.				
Category *	Citation of document, with indication, where appropriate, of the relevant passages					
X,E	Database CAPLUS on STN (Columbus, OH, USA) No. 142:211437, 'Discovery of 2,3,4-trisubstituted pyridine derivatives as potent Akt1 and Akt2 dual inhibitors" agstract, Zhao et al. Biorganic & Medicinal Chemistry Letters (2005), 15(4), 905-909.	1-8, 15-18				
A,P	Database CAPLUS on STN (Columbus, OH, USA) No. 139:350754 Preparation of 2,3-diphenylquinoxaline derivatives as inhibitors of Akt activity for treating cancer' abstract, Bilodeau et al. WO 2003086394, (2003).					
A,P	OTALIGAN No. 120/2/2527 Propagation of					
	r documents are listed in the continuation of Box C. See patent family annex.					
. —	T" later document published after the internal	ational filing date or priority date				
1	and not in conflict with the application b	ut cited to understand the				
particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step						
"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as  "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined						
1.	with one or more other such documents, treferring to an oral disclosure, use, exhibition or other means to a person skilled in the art	seen commission could covere				
"P" document published prior to the international filing date but later than the "&" document member of the same patent family priority date claimed						
Date of the actual completion of the international search  Date of mailing of the international search report						
06 July 2005 (06.07.2005)  Name and mailing address of the ISA/US  Adihorized officer						
Mail Stop PCT, Attn: ISA/US Commissioner for Patents P.O. Box 1450  Telephone No. 571-272-1600						
Alexandria, Virginia 22313-1450  Facsimile No. (703) 305-3230						

## INTERNATIONAL SEARCH REPORT

International application No.

PCT/US04/12188

Box No. II	Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)			
This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:				
ı. 🗌	Claims Nos.: because they relate to subject matter not required to be searched by this Authority, namely.			
2.	Claims Nos.: because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically.			
3.	Claims Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).			
Box No. III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)				
	ional Searching Authority found multiple inventions in this international application, as follows: ontinuation Sheet			
1.	As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.			
2.	As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.			
3.	As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:			
4.	No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.: 1-7, 15-18 in part reading on claim 8			
Remark on	Protest  The additional search fees were accompanied by the applicant's protest.			
1	No protect accompanied the payment of additional coarch fees			

Form PCT/ISA/210 (continuation of first sheet(2)) (January 2004)

INTERN	ATIONAL	SEARCH	REPORT
--------	---------	--------	--------

International application No. PCT/US04/12188

BOX III. OBSERVATIONS WHERE UNITY OF INVENTION IS LACKING

Group I, claims 1-7, 15-18 when Q is benzimidazolone, N-ring is piperidine and claim 8, drawn to benzimidazolonylpiperidines.

Group II, claims 1-7, 15-18 when Q is 2-benzimidazole, N-ring is piperidine and claims 9, 12, drawn to 2-benzimidazolylpiperidines.

Group III, claims 1-7, 15-18 when Q is pyridinylpyrazole, drawn to pyridinylpyrazoles.

Group IV, claims 1-7, 15-18, Q is pyrimidinylpyrazole, and claims 11, 13-14 drawn to pyrimidinylpyrazoles.

Group V, claims 1-7, 15-18 whne Q is alkyl, halogen etc, excluding groups I-IV, drawn to unsubstituted/substituted N-heterocyclic compounds not encompassed by groups I-IV.

Group VI, claim 19, drawn to multiple active ingredient composition.

Group VII, claim 20, drawn to method of treating cancer using combination of drug and radiation.

The inventions listed as Groups I-VII do not relate to a single general inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reasons: PCT Annex B part (f)v indicates that when dealing with alternatives if it can be shown that at least one Markush alternative is not novel over the art the question of unity of invention shall be reconsidered by the examiner. In the instant case, at least one Markush alternative is not novel over Bilodeau et al. Ca 139:350754.

Continuation of B. FIELDS SEARCHED Item 3: CAS-structure EAST/WEST-image